Screener
Recursion Pharmaceuticals, Inc. RXRX Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (134,968) | (176,227) | (263,472) | (367,595) |
| Other income (loss), net | 3,962 | 4,330 | 10,359 | (6,947) |
| Loss before income tax benefit | (131,006) | (171,897) | (253,113) | (374,542) |
| Income tax benefit | 1 | — | 4,604 | 158 |
| Net loss | $(131,005) | $(171,897) | $(248,509) | $(374,384) |
| Per share data | ||||
| Net loss per share of Class A, B and Exchangeable common stock, basic and diluted | $(0.25) | $(0.41) | $(0.47) | $(0.91) |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, basic and diluted | 532,460,085 | 417,361,147 | 530,890,753 | 410,268,199 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s income tax?
- Recursion Pharmaceuticals, Inc. (RXRX) reported income tax of -$1K in Q2 2026.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Recursion Pharmaceuticals, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude